Demographics of Patients Receiving TPOXX for Treatment of Mpox

The data on this page will no longer be updated after 1/25/23.

TPOXX (tecovirimat) use for treatment of mpox is authorized under Food and Drug Administration (FDA) regulations, and CDC holds an expanded access Investigational New Drug (EA-IND) protocol. The IND forms are required to be submitted to CDC. The demographics of patients prescribed TPOXX treatment are based on the patient intake forms CDC has received and abstracted. However, this number underestimates the number of patients who are receiving TPOXX treatment as healthcare providers can start treatment before submitting IND paperwork to CDC.

These data may not reflect the overall population of patients who have been prescribed TPOXX since CDC did not receive forms for every patient treated with TPOXX. Some sections of the submitted forms may also be incomplete.

Patient Intake Forms received and abstracted by CDC with valid non-missing data are included in the above figure. An earlier version of the TPOXX IND Patient Intake form (v5.1) only collected “Sex”. Among the n=Info from CSV patients with valid non-missing values for “Sex” reported to CDC, Info from CSV were “Male” (Info from CSV%) and Info from CSV (Info from CSV%) were “Female”. These values are not included in the above figure.

Patient Intake Forms received and abstracted by CDC with valid non-missing data are included in the above figure.